VK2735

Mechanism

Co-agonism at the GLP-1 and GIP receptors, reducing energy intake through incretin appetite and gastric-emptying pathways.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Body weight reduction
• Incretin co-agonism research
• Obesity trial context

Figures

Every figure below is replotted by this site from values published in the cited paper's text or tables — the numbers are the study's, the drawing is ours, and the evidence rung on each image is the rung of its source.

Half-life, storage & sport

Elimination half-life

not on file — A half-life of approximately 170 to 250 hours after single subcutaneous doses is stated, but only in the sponsor's phase 1 press release, which reports no assay, no sampling schedule, no number of subjects and no dispersion. Nothing in it can be read against the evidence ladder. The one peer-reviewed paper on the compound, the phase 2 VENTURE study, carries no pharmacokinetics section at all.

Literature on file 10

• human RCT
  Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. graded on: a randomised study — “Randomized, 13-Week VENTURE Study”
• review or editorial
  Pharmacological therapies for type 2 diabetes: future approaches. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Paradigm shift in obesity treatment: an extensive review of current pipeline agents. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”

Not graded

5 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  NCT07104383: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight graded on: NCT07104383 is active not recruiting and has posted no results - a registration, not a reported outcome — “NCT07104383”
• not graded
  NCT07104500: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition graded on: NCT07104500 is active not recruiting and has posted no results - a registration, not a reported outcome — “NCT07104500”
• not graded
  NCT06068946: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition graded on: NCT06068946 is completed and has posted no results - a registration, not a reported outcome — “NCT06068946”
• not graded
  NCT06828055: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition graded on: NCT06828055 is completed and has posted no results - a registration, not a reported outcome — “NCT06828055”
• not graded
  NCT05203237: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index graded on: NCT05203237 is completed and has posted no results - a registration, not a reported outcome — “NCT05203237”

What is circulated not evidence 2

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose occasional nothing on file either way

  Aggregator dose charts circulate a 2.5 mg weekly subcutaneous starting dose for VK2735, reconstituted with 2 mL of bacteriostatic water.

  2.5 mg

  On the record No dosing record exists on file for VK2735; the compound record holds only body-weight reduction, incretin co-agonism research and obesity trial context. Phase 3 arms reported publicly are 7.5, 12.5 and 17.5 mg weekly, so the circulated 2.5 mg start matches no published arm.

  Source 1

• unverified community data sourcing occasional nothing on file either way

  VK2735 appears in grey-market peptide dose charts alongside approved compounds despite being a phase 3 investigational drug with no label and no published community dosing basis.

  2 mL

  On the record Nothing on file supports any vial format, reconstitution or storage claim for VK2735.

  Source 1